|
| Press Releases |
|
 |
|
| Wednesday, August 21, 2024 |
|
|
Positive Interim Blood Sugar Results From Lexaria's GLP-1 Diabetes Animal Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received 4-week and 8-week blood glucose results from ongoing animal study WEIGHT-A24-1 (the "Study"). more info >> |
|
| Monday, August 19, 2024 |
|
|
Positive Results from Lexaria's Molecular Characterization Study Monomeric form of GLP-1 drug preserved by DehydraTECH |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive findings from its applied research program together with the National Research Council of Canada ("NRC") that evaluated important mode of action facets of DehydraTECH processed with the glucagon-peptide 1 ("GLP-1") drug, semaglutide. more info >> |
|
| Monday, July 8, 2024 |
|
|
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces three new patent awards. more info >> |
|
| Wednesday, May 8, 2024 |
|
|
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") is underway and the first dosing visit for all nine study participants has already concluded. more info >> |
|
| Monday, May 6, 2024 |
|
|
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 ("GLP-1") drug, semaglutide, related to its mode of action and performance. more info >> |
|
| Tuesday, April 16, 2024 |
|
|
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces approval has been received from an independent third-party ethics review board, for human pilot study #2 (the "Study"), investigating GLP-1 drugs and DehydraTECH. more info >> |
|
| Tuesday, April 2, 2024 |
|
|
Lexaria Awarded New Patents |
| more info >> |
|
| Thursday, March 14, 2024 |
|
|
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer |
| Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately. more info >> |
|
| Thursday, March 7, 2024 |
|
|
Lexaria Awards Contract For Next GLP-1 Human Pilot Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("CRO") to perform the Company's second DehydraTECH-powered glucagon-like peptide 1 ("GLP-1") human pilot study #2 (the "Study"). more info >> |
|
| Tuesday, March 5, 2024 |
|
|
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 |
| more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Autobrains and JOYNEXT Revolutionize Smart Camera Solution Powered by Autobrains' Affordable Safety ADAS Software
Dec 4, 2024 17:00 HKT/SGT
|
|
|
DENSO Signs Memorandum of Understanding with Canatu of Finland for Practical Application of Carbon Nanotube Technology
Dec 4, 2024 17:51 JST
|
|
|
Sweetness Affecting Both the Young and Old: Prevent Diabetes with LAC This World Diabetes Day
Dec 4, 2024 14:30 HKT/SGT
|
|
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Dec 4, 2024 12:08: JST
|
|
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Dec 4, 2024 11:08 HKT/SGT
|
|
|
雲頂新耀宣佈治療原發性膜性腎病的新型BTK抑制劑EVER001在1b/2a期臨床試驗階段性數據中取得積極結果
Dec 4, 2024 10:59 HKT/SGT
|
|
|
云顶新耀宣布治疗原发性膜性肾病的新型BTK抑制剂EVER001在1b/2a期临床试验阶段性数据中取得积极结果
Dec 4, 2024 10:48 HKT/SGT
|
|
|
富士通、UNHCRフィリッポ・グランディ国連難民高等弁務官と難民支援に関する意見交換を実施
Dec 4, 2024 10:00: JST
|
|
|
DeAgentAI and OKX Wallet Join Forces: $50K DA Token Airdrop for Web3 Enthusiasts
Dec 4, 2024 09:45 HKT/SGT
|
|
|
Japan Maritime Defense Force Selects SeaGuardians From GA-ASI
Dec 4, 2024 08:00 HKT/SGT
|
|
|
Military Metals Responds to China's Export Ban on Critical Minerals
Dec 4, 2024 02:39 HKT/SGT
|
|
|
Machine learning used to optimise polymer production
Dec 3, 2024 23:15 HKT/SGT
|
|
|
Spritzer Clinches 10th Consecutive "Brand of the Year" Award at the World Branding Awards in London
Dec 3, 2024 23:00 HKT/SGT
|
|
|
Acme, Founder of ACET, Calling on Thailand's Embrace of Digital Assets
Dec 3, 2024 22:00: JST
|
|
|
Acme, Founder of ACET, Calling on Thailand's Embrace of Digital Assets
Dec 3, 2024 21:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
